Do analysts prefer XCUR or CNTX?

Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,566.67%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has better earnings & valuation, XCUR or CNTX?

Exicure is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure N/A N/A -$4.95M -$1.32 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is XCUR or CNTX more profitable?

Context Therapeutics' return on equity of -82.06% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Context Therapeutics N/A -82.06% -72.74%

Does the media refer more to XCUR or CNTX?

In the previous week, Exicure had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Exicure and 1 mentions for Context Therapeutics. Exicure's average media sentiment score of 0.17 beat Context Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer XCUR or MDXH?

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 261.11%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is XCUR or MDXH more profitable?

Exicure has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% MDxHealth -33.46% N/A -24.25%

Do analysts rate GOSS or XCUR?

Gossamer Bio currently has a consensus target price of $256.00, indicating a potential upside of 2,169.50%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GOSS or XCUR more profitable?

Exicure has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% Exicure N/A -237.91% -61.98%

Does the media prefer GOSS or XCUR?

In the previous week, Gossamer Bio had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Gossamer Bio and 3 mentions for Exicure. Exicure's average media sentiment score of 0.17 beat Gossamer Bio's score of 0.14 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ALGS or XCUR?

Aligos Therapeutics presently has a consensus price target of $38.50, suggesting a potential upside of 601.28%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ALGS or XCUR?

In the previous week, Exicure had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Exicure and 2 mentions for Aligos Therapeutics. Exicure's average media sentiment score of 0.17 beat Aligos Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCTX or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BCTX or XCUR?

Exicure is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Exicure N/A N/A -$4.95M -$1.32 N/A

Is BCTX or XCUR more profitable?

Briacell Therap's return on equity of -153.53% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Exicure N/A -237.91% -61.98%

Does the media favor BCTX or XCUR?

In the previous week, Exicure had 2 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for Exicure and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.21 beat Exicure's score of 0.17 indicating that Briacell Therap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Exicure (XCUR) Competitors

$1.26 +0.03 (+2.44%)

As of 04:00 PM Eastern

Compare

XCUR vs. CNTX, MDXH, GOSS, ALGS, and BCTX

Should you buy Exicure stock or one of its competitors? Exicure's main competitors and comparable companies include Context Therapeutics (CNTX), MDxHealth (MDXH), Gossamer Bio (GOSS), Aligos Therapeutics (ALGS), and Briacell Therap (BCTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exicure compare to Context Therapeutics?

Exicure (NASDAQ:XCUR) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Exicure has a beta of 3.63, suggesting that its share price is 263% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

In the previous week, Exicure had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Exicure and 1 mentions for Context Therapeutics. Exicure's average media sentiment score of 0.17 beat Context Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,566.67%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Exicure is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	N/A	N/A	-$4.95M	-$1.32	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Context Therapeutics' return on equity of -82.06% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Context Therapeutics	N/A	-82.06%	-72.74%

42.8% of Exicure shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Exicure beats Context Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Exicure compare to MDxHealth?

Exicure (NASDAQ:XCUR) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Exicure has higher earnings, but lower revenue than MDxHealth. Exicure is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	N/A	N/A	-$4.95M	-$1.32	N/A
MDxHealth	$114.02M	0.26	-$33.52M	-$0.72	N/A

42.8% of Exicure shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 261.11%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Exicure has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
MDxHealth	-33.46%	N/A	-24.25%

In the previous week, Exicure had 3 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Exicure and 0 mentions for MDxHealth. Exicure's average media sentiment score of 0.17 beat MDxHealth's score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Neutral
MDxHealth	Neutral

Exicure has a beta of 3.63, meaning that its share price is 263% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

Summary

MDxHealth beats Exicure on 8 of the 15 factors compared between the two stocks.

How does Exicure compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Exicure has lower revenue, but higher earnings than Gossamer Bio. Exicure is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.68	-$170.37M	-$56.00	N/A
Exicure	N/A	N/A	-$4.95M	-$1.32	N/A

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Gossamer Bio has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Exicure has a beta of 3.63, indicating that its stock price is 263% more volatile than the broader market.

Exicure has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Exicure	N/A	-237.91%	-61.98%

In the previous week, Gossamer Bio had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Gossamer Bio and 3 mentions for Exicure. Exicure's average media sentiment score of 0.17 beat Gossamer Bio's score of 0.14 indicating that Exicure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exicure	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio currently has a consensus target price of $256.00, indicating a potential upside of 2,169.50%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Gossamer Bio beats Exicure on 8 of the 15 factors compared between the two stocks.

How does Exicure compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Aligos Therapeutics presently has a consensus price target of $38.50, suggesting a potential upside of 601.28%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Exicure had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Exicure and 2 mentions for Aligos Therapeutics. Exicure's average media sentiment score of 0.17 beat Aligos Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exicure	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aligos Therapeutics has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, Exicure has a beta of 3.63, suggesting that its stock price is 263% more volatile than the broader market.

Exicure has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Exicure	N/A	-237.91%	-61.98%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exicure has lower revenue, but higher earnings than Aligos Therapeutics. Exicure is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$31.52M	1.09	-$24.19M	-$7.30	N/A
Exicure	N/A	N/A	-$4.95M	-$1.32	N/A

Summary

Aligos Therapeutics and Exicure tied by winning 8 of the 16 factors compared between the two stocks.

How does Exicure compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Exicure had 2 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for Exicure and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.21 beat Exicure's score of 0.17 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exicure	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Exicure is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Exicure	N/A	N/A	-$4.95M	-$1.32	N/A

Briacell Therap has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Exicure has a beta of 3.63, indicating that its share price is 263% more volatile than the broader market.

Briacell Therap's return on equity of -153.53% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Exicure	N/A	-237.91%	-61.98%

Summary

Exicure beats Briacell Therap on 7 of the 10 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.25M	$3.92B	$7.26B	$13.23B
Dividend Yield	N/A	3.64%	2.53%	12.80%
P/E Ratio	-0.95	14.19	275.56	25.79
Price / Sales	N/A	1,580.83	693.67	102.99
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	2.03	15.60	10.56	6.36
Net Income	-$4.95M	-$22.86M	$3.49B	$358.17M
7 Day Performance	-8.03%	-1.24%	-0.23%	0.54%
1 Month Performance	9.57%	-4.56%	-2.80%	-2.95%
1 Year Performance	-67.19%	38.32%	18.25%	6.08%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	0.9786 of 5 stars	$1.26 +2.4%	N/A	-68.0%	$8.25M	N/A	N/A	50
CNTX Context Therapeutics	2.4076 of 5 stars	$0.38 +4.0%	$6.17 +1,527.1%	-62.0%	$34.82M	N/A	N/A	7	Gap Up
MDXH MDxHealth	2.1297 of 5 stars	$0.68 +1.1%	$2.17 +218.3%	-84.8%	$33.70M	$107.88M	N/A	300
GOSS Gossamer Bio	2.4949 of 5 stars	$10.96 +5.6%	$256.00 +2,235.8%	-95.6%	$32.11M	$48.47M	N/A	180	News Coverage Analyst Downgrade Gap Up
ALGS Aligos Therapeutics	2.2084 of 5 stars	$5.05 +1.2%	$38.50 +662.4%	-45.8%	$31.51M	$2.19M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. CNTX, MDXH, GOSS, ALGS, and BCTX

How does Exicure compare to Context Therapeutics?

Summary

How does Exicure compare to MDxHealth?

Summary

How does Exicure compare to Gossamer Bio?

Summary

How does Exicure compare to Aligos Therapeutics?

Summary

How does Exicure compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. CNTX, MDXH, GOSS, ALGS, and BCTX

How does Exicure compare to Context Therapeutics?

Which has more risk & volatility, XCUR or CNTX?

Does the media refer more to XCUR or CNTX?

Do analysts prefer XCUR or CNTX?

Which has better earnings & valuation, XCUR or CNTX?

Is XCUR or CNTX more profitable?

Do insiders & institutionals believe in XCUR or CNTX?

Summary

How does Exicure compare to MDxHealth?

Which has higher earnings and valuation, XCUR or MDXH?

Do institutionals and insiders believe in XCUR or MDXH?

Do analysts prefer XCUR or MDXH?

Is XCUR or MDXH more profitable?

Does the media favor XCUR or MDXH?

Which has more risk and volatility, XCUR or MDXH?

Summary

How does Exicure compare to Gossamer Bio?

Which has stronger earnings & valuation, GOSS or XCUR?

Do institutionals & insiders believe in GOSS or XCUR?

Which has more volatility and risk, GOSS or XCUR?

Is GOSS or XCUR more profitable?

Does the media prefer GOSS or XCUR?

Do analysts rate GOSS or XCUR?

Summary

How does Exicure compare to Aligos Therapeutics?

Do analysts prefer ALGS or XCUR?

Does the media refer more to ALGS or XCUR?

Which has more volatility & risk, ALGS or XCUR?

Is ALGS or XCUR more profitable?

Do institutionals & insiders hold more shares of ALGS or XCUR?

Which has stronger earnings and valuation, ALGS or XCUR?

Summary

How does Exicure compare to Briacell Therap?

Do analysts rate BCTX or XCUR?

Does the media favor BCTX or XCUR?

Do insiders & institutionals hold more shares of BCTX or XCUR?

Which has higher earnings & valuation, BCTX or XCUR?

Which has more risk & volatility, BCTX or XCUR?

Is BCTX or XCUR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools